Belatacept and Risk of PTLD in US Renal Transplant Recipients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Belatacept (Primary) ; Calcineurin inhibitors
- Indications Renal transplant rejection
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 28 Jan 2016 Planned End Date changed from 1 Jan 2017 to 1 Jun 2018, according to ClinicalTrials.gov record.
- 28 Jan 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018, according to ClinicalTrials.gov record.
- 14 Aug 2012 New trial record